Dupixent® (dupilumab) Phase 3 Results Show Sustained

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose...

Related Keywords

Paris ,France General ,France ,New York ,United States ,Japan ,Tarrytown ,Mirna Chehade ,Regeneron Velocimmune ,Georged Yancopoulos ,Nasdaq ,Euronext ,Exchange Commission ,Icahn School Of Medicine At Mount Sinai ,Regeneron Genetics Center ,Regeneron Velocimmune Technology ,American College Of Gastroenterology ,Dupilumab Development Program ,Regeneron Pharmaceuticals Inc ,Mount Sinai Center ,Drug Administration ,Linkedin ,Priority Review ,American College ,Eosinophilic Disorders ,Icahn School ,Mount Sinai ,Biologics License Application ,Dupixent Pediatric Eosinophilic Esophagitis Trial ,Chief Scientific Officer George ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Nasdaq Regn ,Nc ,